Genomic Health, Inc. (NASDAQ:GHDX) – Equities researchers at Jefferies Group upped their FY2019 earnings estimates for shares of Genomic Health in a research report issued to clients and investors on Thursday. Jefferies Group analyst B. Couillard now forecasts that the medical research company will post earnings per share of $0.75 for the year, up from their prior forecast of $0.67. Jefferies Group also issued estimates for Genomic Health’s FY2020 earnings at $0.92 EPS.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Thursday, March 8th. The medical research company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $87.50 million for the quarter, compared to analyst estimates of $88.96 million. Genomic Health had a negative return on equity of 0.85% and a negative net margin of 1.13%. Genomic Health’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.04 EPS.
Shares of Genomic Health (NASDAQ:GHDX) opened at $33.11 on Monday. Genomic Health has a 12 month low of $26.54 and a 12 month high of $37.50.
In other Genomic Health news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $29.94, for a total value of $149,700.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Laura Leber sold 21,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $33.29, for a total transaction of $699,090.00. The disclosure for this sale can be found here. Insiders sold 89,280 shares of company stock worth $2,961,996 in the last 90 days. 46.20% of the stock is owned by company insiders.
Several large investors have recently made changes to their positions in the business. Parametric Portfolio Associates LLC boosted its position in shares of Genomic Health by 5.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after acquiring an additional 441 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Genomic Health by 3.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock worth $516,000 after purchasing an additional 520 shares during the last quarter. Voya Investment Management LLC raised its holdings in Genomic Health by 18.5% during the 2nd quarter. Voya Investment Management LLC now owns 8,622 shares of the medical research company’s stock worth $281,000 after purchasing an additional 1,344 shares during the last quarter. Meeder Asset Management Inc. raised its holdings in Genomic Health by 120.7% during the 4th quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock worth $101,000 after purchasing an additional 1,619 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in Genomic Health by 9.6% during the 3rd quarter. New York State Common Retirement Fund now owns 22,900 shares of the medical research company’s stock worth $735,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors own 91.18% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Jefferies Group Brokers Boost Earnings Estimates for Genomic Health, Inc. (GHDX)” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3257075/jefferies-group-brokers-boost-earnings-estimates-for-genomic-health-inc-ghdx.html.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.